Barclays Forecasts Strong Price Appreciation for Pacific Biosciences of California (NASDAQ:PACB) Stock

Pacific Biosciences of California (NASDAQ:PACB) had its price objective increased by Barclays from $1.25 to $2.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has an “underweight” rating on the biotechnology company’s stock. Barclays‘s price objective suggests a potential downside of 18.53% from the stock’s current price.

Several other equities analysts have also issued reports on PACB. UBS Group initiated coverage on Pacific Biosciences of California in a research report on Wednesday, September 9th. They set a “neutral” rating and a $1.35 price target on the stock. Weiss Ratings raised Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. Piper Sandler restated a “neutral” rating and issued a $3.00 target price (up from $2.00) on shares of Pacific Biosciences of California in a report on Thursday. Finally, Wall Street Zen cut shares of Pacific Biosciences of California from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $2.09.

Pacific Biosciences of California Price Performance

Pacific Biosciences of California stock traded down $0.10 during mid-day trading on Thursday, hitting $2.46. The company’s stock had a trading volume of 14,948,734 shares, compared to its average volume of 8,316,060. The business has a 50 day moving average price of $1.89 and a 200-day moving average price of $1.62. Pacific Biosciences of California has a 12 month low of $1.07 and a 12 month high of $3.43. The stock has a market cap of $763.09 million, a price-to-earnings ratio of -5.64 and a beta of 2.21.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The firm had revenue of $40.56 million for the quarter, compared to analysts’ expectations of $39.31 million. Pacific Biosciences of California had a negative return on equity of 5,752.12% and a negative net margin of 82.49%. On average, equities research analysts expect that Pacific Biosciences of California will post -0.52 earnings per share for the current fiscal year.

Insider Activity

In other Pacific Biosciences of California news, insider James R. Gibson II sold 661,815 shares of the stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $3.11, for a total value of $2,058,244.65. Following the completion of the sale, the insider owned 1,083,848 shares in the company, valued at approximately $3,370,767.28. This trade represents a 37.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Van Oene sold 26,911 shares of Pacific Biosciences of California stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1.13, for a total value of $30,409.43. Following the completion of the sale, the insider owned 2,705,853 shares in the company, valued at approximately $3,057,613.89. This represents a 0.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.70% of the stock is owned by company insiders.

Institutional Trading of Pacific Biosciences of California

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PACB. BlackRock Inc. purchased a new position in shares of Pacific Biosciences of California in the second quarter worth $54,330,000. Bank of America Corp DE bought a new stake in Pacific Biosciences of California during the second quarter worth approximately $2,265,000. Hhlr Advisors LTD. purchased a new stake in Pacific Biosciences of California during the 2nd quarter valued at $1,544,000. Dimensional Fund Advisors LP lifted its holdings in shares of Pacific Biosciences of California by 177.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 899,550 shares of the biotechnology company’s stock worth $1,187,000 after acquiring an additional 575,801 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Pacific Biosciences of California in the second quarter worth about $1,290,000.

Key Pacific Biosciences of California News

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: PacBio reported a Q3 loss of $0.11 per share, narrower than the $0.13 loss analysts expected, while revenue of $40.56 million topped the $39.31 million consensus. The loss was also slightly smaller than the $0.12 per share reported a year earlier. Zacks Q3 earnings report
• Positive Sentiment: Recent coverage points to clinical adoption and AI partnerships as contributors to steady growth, supporting the longer-term business outlook. Q3 2026 business overview
• Neutral Sentiment: Piper Sandler kept its “neutral” rating but raised its price target to $3 from $2, indicating a higher valuation estimate without a change in its recommendation. Piper Sandler rating information
• Negative Sentiment: PacBio narrowed its 2026 revenue guidance to $155 million–$160 million and is targeting cash-flow breakeven in 2028. The distant breakeven goal underscores that substantial cash-flow improvement remains ahead, despite the quarterly beat. Revenue guidance and breakeven outlook

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.